Rafael Holdings owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. Co. has investments in Rafael Pharmaceuticals, Inc., a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Co. also has an investment in its subsidiary, LipoMedix Pharmaceuticals Ltd., which is based in Israel, and is a clinical stage oncology company. In addition, Co.'s wholly-owned venture, Barer Institute, is focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The RFL stock yearly return is shown above.
The yearly return on the RFL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RFL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|